Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration GlobeNewswire - Thu Mar 27, 3:01PM CDT

BEAM : 22.19 (+1.28%)
Beam Therapeutics Announces Pricing of Underwritten Offering GlobeNewswire - Mon Mar 10, 5:01AM CDT

BEAM : 22.19 (+1.28%)
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation GlobeNewswire - Mon Mar 10, 5:00AM CDT

BEAM : 22.19 (+1.28%)
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts GlobeNewswire - Tue Feb 25, 6:00AM CST

BEAM : 22.19 (+1.28%)
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences GlobeNewswire - Mon Feb 24, 6:00AM CST

BEAM : 22.19 (+1.28%)
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference GlobeNewswire - Thu Jan 30, 6:00AM CST

BEAM : 22.19 (+1.28%)
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
Is it a Good Idea to Invest in Beam Therapeutics Stock Now? Zacks Investment Research - Fri Jan 24, 10:40AM CST

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.BEAM’s...

BEAM : 22.19 (+1.28%)
VYGR : 3.74 (+2.75%)
CSTL : 20.10 (+0.10%)
HRMY : 33.35 (+0.42%)
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR GlobeNewswire - Thu Jan 23, 6:00AM CST

BEAM : 22.19 (+1.28%)
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? Zacks Investment Research - Mon Jan 13, 10:52AM CST

One stock that might be an intriguing choice for investors right now is Beam Therapeutics Inc. BEAM This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings...

BEAM : 22.19 (+1.28%)
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts GlobeNewswire - Mon Jan 13, 6:00AM CST

BEAM : 22.19 (+1.28%)

Barchart Exclusives

Marjorie Taylor Greene Loves This High-Yield Dividend Stock. Should You Buy It Too? Barchart - Thu Mar 27, 6:30PM CDT
Congresswoman Marjorie Taylor Greene’s recent investment in Devon Energy has brought attention to the stock, which boasts a strong financial performance, attractive valuation, and growing dividend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot